FDA NEWS RELEASE
For Immediate Release: May 20, 2011
Media Inquiries: Erica Jefferson, 301-796-4988, firstname.lastname@example.org
Consumer Inquiries: 888-INFO-FDA
FDA approves new HIV treatment
The U.S. Food and Drug Administration today approved Edurant (rilpivirine) in combination with other antiretroviral drugs for the treatment of HIV-1 infection in adults who have never taken HIV therapy (treatment-na茂ve).
Edurant belongs to a class of HIV drugs called non-nucleoside reverse transcriptase inhibitor (NNRTI). The drug works by blocking HIV viral replication. Edurant is to be used as part of a highly active antiretroviral therapy (HAART) regimen that is designed to suppress the amount of HIV (viral load) in the blood. Edurant is a pill taken once a day with food.